공고 • Jun 30
InventisBio Co., Limited to Report First Half, 2026 Results on Aug 21, 2026 InventisBio Co., Limited announced that they will report first half, 2026 results on Aug 21, 2026 공고 • May 29
InventisBio Co., Limited, Annual General Meeting, Jun 18, 2026 InventisBio Co., Limited, Annual General Meeting, Jun 18, 2026, at 10:00 China Standard Time. Location: No. 63, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai China Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Wen Chen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Apr 16
InventisBio Co., Limited announced that it expects to receive CNY 300 million in funding InventisBio Co., Ltd. announced private placement to issue A shares for gross proceeds of not more than CNY 300,000,000 on April 14, 2026. the transaction includes participation from not more than 35 investors. The issue price not less than 80% of the average price in the 20 trading days before the pricing reference date. The shares cannot be transferred within 6 months from the issuance closing date. The transaction is approved by board of directors of the company in it's 4th Meeting of 2026 of the 2nd Directorate and is subject to approval of shareholders, will be submitted to the Company’s Annual Shareholders Meeting of 2025 for approval. 공고 • Mar 30
InventisBio Co., Limited to Report Q1, 2026 Results on Apr 29, 2026 InventisBio Co., Limited announced that they will report Q1, 2026 results on Apr 29, 2026 공고 • Dec 26
InventisBio Co., Limited to Report Fiscal Year 2025 Results on Mar 28, 2026 InventisBio Co., Limited announced that they will report fiscal year 2025 results on Mar 28, 2026 공고 • Sep 30
InventisBio Co., Limited to Report Q3, 2025 Results on Oct 30, 2025 InventisBio Co., Limited announced that they will report Q3, 2025 results on Oct 30, 2025 공고 • Jun 30
InventisBio Co., Limited to Report First Half, 2025 Results on Aug 23, 2025 InventisBio Co., Limited announced that they will report first half, 2025 results on Aug 23, 2025 공고 • May 30
InventisBio Co., Limited, Annual General Meeting, Jun 20, 2025 InventisBio Co., Limited, Annual General Meeting, Jun 20, 2025, at 09:30 China Standard Time. 공고 • Mar 28
InventisBio Co., Limited to Report Q1, 2025 Results on Apr 29, 2025 InventisBio Co., Limited announced that they will report Q1, 2025 results on Apr 29, 2025 공고 • Dec 27
InventisBio Co., Limited to Report Fiscal Year 2024 Results on Apr 26, 2025 InventisBio Co., Limited announced that they will report fiscal year 2024 results on Apr 26, 2025 공고 • Dec 03
InventisBio Co., Ltd. Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis InventisBio Co. Ltd. announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. The randomized, multicenter, double-blind, placebo-controlled study demonstrated that D-2570 achieved significant efficacy in improving skin clearance while maintaining a favorable safety profile. Key Findings: 85% of patients treated with D-2570 in all three dose groups achieved PASI 75 (75% or greater improvement in the Psoriasis Area and Severity Index) by week 12, compared to 12.5% in placebo group. 50% of patients receiving the high dose of D-2570 achieved PASI 100 (complete skin clearance) by week 12, compared To 2.5% in placebo group; PASI 90 and sPGA 0/1 responses also significantly favored D-2570 over placebo, with 77.5% and 87.5%, respectively, in the high-dose group, versus 5.0% and 20%, respectively, in placebo group. The trial enrolled 161 patients randomized to three dose levels of D-2570 or placebo. The primary endpoint of PASI 75 was achieved by a significantly greater proportion of patients in all D-2570 dose groups compared to placebo (p<0.001). Superior efficacy was observed across secondary endpoints, including PASI 90, PASI 100, and static Physician's Global Assessment (sPGA) 0/1. Safety Profile: D-2570 was well-tolerated, with no serious adverse events reported. The majority of adverse events were mild to moderate (CTCAE Grade 1 or 2), and no new safety signals were identified. The safety profile was consistent with other TYK2 inhibitors that are approved or currently in clinical development. The complete data from this Phase 2 trial will be presented at upcoming scientific conferences. Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.16 loss per share (vs CN¥0.13 loss in 3Q 2023) Third quarter 2024 results: CN¥0.16 loss per share (further deteriorated from CN¥0.13 loss in 3Q 2023). Revenue: CN¥4.28m (down 91% from 3Q 2023). Net loss: CN¥91.1m (loss widened 24% from 3Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. 공고 • Sep 30
InventisBio Co., Limited to Report Q3, 2024 Results on Oct 30, 2024 InventisBio Co., Limited announced that they will report Q3, 2024 results on Oct 30, 2024 Buy Or Sell Opportunity • Sep 27
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to CN¥8.42. The fair value is estimated to be CN¥6.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last year. Earnings per share has grown by 24%. Revenue is forecast to grow by 220% in 2 years. Earnings are forecast to grow by 88% in the next 2 years. 공고 • Jun 28
InventisBio Co., Limited to Report First Half, 2024 Results on Aug 23, 2024 InventisBio Co., Limited announced that they will report first half, 2024 results on Aug 23, 2024 공고 • Jun 02
InventisBio Co., Limited, Annual General Meeting, Jun 21, 2024 InventisBio Co., Limited, Annual General Meeting, Jun 21, 2024, at 10:00 China Standard Time. Buy Or Sell Opportunity • May 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to CN¥8.60. The fair value is estimated to be CN¥10.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 81% in 2 years. Earnings are forecast to grow by 48% in the next 2 years. New Risk • May 01
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (CN¥352m net loss next year). 공고 • Mar 30
InventisBio Co., Limited to Report Q1, 2024 Results on Apr 30, 2024 InventisBio Co., Limited announced that they will report Q1, 2024 results on Apr 30, 2024 New Risk • Jul 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥544m net loss in 2 years). Share price has been volatile over the past 3 months (8.0% average weekly change). 공고 • Jun 28
InventisBio Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023 InventisBio Co., Ltd. announced that they will report first half, 2023 results on Aug 22, 2023 
